匹伐他汀对2型糖尿病脂代谢紊乱的调脂作用研究

Clinical Study of Pitavastatin in the Treatment of Type 2 Diabetes Dyslipidoses

目的:研究匹伐他汀对2型糖尿病脂代谢紊乱的调脂作用。方法:80例2型糖尿病脂代谢紊乱患者随机分为对照组与治疗组,各40例,在常规治疗基础上,对照组加用洛伐他汀片,治疗组加用匹伐他汀钙片,疗程12周。考察治疗前、后血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、糖化血红蛋白(HbA1c)、血压(BP)、心率(HR)及体重指数(BMI)、天门冬酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、γ-谷氨酰转移酶(GGT)的变化。结果:2组治疗后TC、TG、LDL-C均较治疗前明显下降(P<0.05),治疗组的降低程度更大,差异有统计学意义(P<0.05)。2组治疗后HDL-C均较治疗前明显提高(P<0.05),治疗组的升高程度更大,差异有统计学意义(P<0.05)。2组治疗后HbA1c、收缩压(SBP)、HR、BMI及AST、ALT均下降,但治疗前、后及治疗后2组间比较差异均无统计学意义(P>0.05)。与对照组比较,治疗组GGT升高,但差异无统计学意义(P>0.05)。结论:匹伐他汀可改善2型糖尿病患者的脂代谢紊乱状态,对血糖、血压、HR、BMI及肝酶谱无明显影响。

OBJECTIVE：To observe the clinical efficacy and safety of pitavastatin in the treatment of type 2 diabetes dyslipidoses.METHODS：80 patients with type 2 diabetes dyslipidoses were randomly divided into control group and treatment group with each group of 40 cases.On the basis of conventional treatment,control group was additional treated with Lovastatin tablets,and treatment group was treated with Pitavastatin tablets for 12 weeks.The changes of blood cholesterol （TC）,triglyceride （TG）,low density lipoprotein cholesterol （LDL-C）,high density lipoprotein cholesterol （HDL-C）,HbA1c,blood pressure （BP）,heart rate（HR）,body mass index（BMI）,aspartate transaminase （AST）,alanine amiotransferase （ALT） and γ-glutamyl transpeptadase （GGT） were observed before and after treatment.RESULTS：The levels of TC,TG,LDL-C were all decreased in two groups after treatment（P0.05）.The decrease of TC,TG and LDL-C levels in treatment group was more significant than in control group,there was significant difference（P0.05）.The level of HDL-C in two groups was increased significantly after treatment（P0.05）,especially in treatment group.There was significant difference （P0.05）.The levels of HbA1c,SBP,HR,BMI,AST and ALT were all decreased in two groups after treatment,but there was no significant difference between 2 groups before and after treatment（P0.05）.Compared with control group,the level of GGT in treatment group was increased,but there was no significant difference （P0.05）.CONCLUSION：Pitavastatin can improve types 2 diabetes dyslipidoses,and has little effect on blood glucose,BP,HR,BMI,and enzyme spectrum of liver.